Introduction
============

Regulatory T cells (Tregs) are a subgroup of T cells that suppress proliferation of effector T cells, sustain tolerance to self-antigens and regulate the immune system ([@b1-mmr-17-03-3647]). As a type of T cell that expresses cluster of differentiation (CD)4, CD25 and forkhead box P3 (FOXP3), human FOXP3^+^CD25^+^CD4^+^ Tregs are critical for maintaining immune homeostasis ([@b2-mmr-17-03-3647]). Tregs are deemed to inhibit tumor immunity and contribute to the growth of cancerous cells, suggesting that high levels of Tregs may indicate poor prognosis for patients with cancer ([@b3-mmr-17-03-3647]). A previous study also demonstrated that regulation of Tregs is conducive to autoimmune disease and organ transplantation ([@b4-mmr-17-03-3647]). Therefore, it is necessary to explore the mechanisms implicated in Treg function.

Numerous genes have been reported to be associated with Treg function. For example, cytotoxic T lymphocyte antigen 4 may be important for the immune suppression of natural Tregs by affecting the activation effects of antigen-presenting cells on other T cells ([@b5-mmr-17-03-3647]--[@b7-mmr-17-03-3647]). Ectopic expression of lymphocyte-activation gene 3 can significantly weaken the proliferative capacity of CD4^+^ T cells and facilitate their inhibitory effect on effector T cells ([@b8-mmr-17-03-3647]). Prostaglandin E~2~ (PGE2) promotes the mRNA and protein expression of *FOXP3* and increases its promoter activity, thus suggesting that PGE2 in human lymphocytes may regulate *FOXP3* expression and the function of Tregs ([@b9-mmr-17-03-3647],[@b10-mmr-17-03-3647]). *In vivo*, toll-like receptor 2 (*TLR2*) modulates Treg function, thus indicating that TLRs may control immune responses via Tregs ([@b11-mmr-17-03-3647],[@b12-mmr-17-03-3647]). Furthermore, a previous study demonstrated that indoleamine 2,3-dioxygenase 1 predominantly controls the response of Tregs to inflammatory stimuli in the physiological environment ([@b13-mmr-17-03-3647]). Latent transforming growth factor-β is expressed on activated Tregs, and may serve a role in mechanisms underlying infectious tolerance and Treg-mediated suppression ([@b14-mmr-17-03-3647]). In 2012, He *et al* ([@b15-mmr-17-03-3647]) performed high time-resolution genome-wide gene expression analysis to investigate the genes involved in human Tregs; the results demonstrated that plasminogen activator urokinase was essential for the suppressive function of Tregs. Nevertheless, the potential molecular mechanisms underlying Treg function remain unclear.

The present study, using data deposited by He *et al* ([@b15-mmr-17-03-3647]), further identified the key genes implicated in Treg function. After searching the microRNA (miRNA)-mRNA pairs, transcription factor (TF)-mRNA pairs and protein-protein interaction (PPI) relationships, regulatory networks and PPI networks were constructed and merged into integrated networks. Finally, enrichment analyses were performed for the genes involved in the PPI networks to predict their possible functions.

Materials and methods
=====================

### Microarray data

GSE11292 microarray data were downloaded from the Gene Expression Omnibus (GEO, <http://www.ncbi.nlm.nih.gov/geo/>) database, based on the GPL570 \[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array platform (Affymetrix, Inc., Santa Clara, CA, USA). To investigate the key genes important for human Treg function, data from Treg cells at 19 time points (0--360 min) with an equal interval of 20 min, and their corresponding repeated samples, were collected from GSE11292. Notably, data from Treg cells at the 120 min time point were missing. Briefly, the stable human Tregs isolated from peripheral blood were from the same batch of Tregs as used in a previous study by Probst-Kepper *et al* ([@b16-mmr-17-03-3647]). Tregs were cultured in Iscove\'s modified Dulbecco\'s medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing 10% fetal calf serum (Gibco; Thermo Fisher Scientific, Inc.), 50 µM µ-mercaptoethanol (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), 100 µg/ml streptomycin and 100 U/ml penicillin. Human Tregs were added with anti-CD3/anti-CD28-coated Dynabeads (Invitrogen; Thermo Fisher Scientific, Inc.) in a proportion of 1:1 and interleukin-2 (IL2; 100 U/ml; Novartis International AG, Basel, Switzerland) and were assigned into 1.5 ml microtubes (Eppendorf, Hamburg, Germany; 4×10^6^ cells/tube) for each time point. The cells were stored at 4°C to settle the cells and beads, and then were cultured at 37°C ([@b15-mmr-17-03-3647]). GSE11292 data used in the present study were downloaded from the public GEO database; therefore, ethical approval and patient consent were not required.

### Data preprocessing and clustering analysis

Using the Affy package ([@b17-mmr-17-03-3647]) in R, the raw data were preprocessed with background correction, quantile normalization, probe summarization and transformation from probe ID to gene symbol. Subsequently, soft clustering analysis was performed for the two group samples (Treg cells and their repeated samples) using the Mfuzz package ([@b18-mmr-17-03-3647],[@b19-mmr-17-03-3647]). The parameters of minimum standard deviation and acore were set at 0.5 and 0.9, respectively.

### Construction of regulatory networks

Combined with the validated miRNA-mRNA pairs in miRecords database (<http://c1.accurascience.com/miRecords/>) ([@b20-mmr-17-03-3647]), and the predicted miRNA-mRNA pairs in miRanda (<http://www.microrna.org>) ([@b21-mmr-17-03-3647]), MirTarget2 ([http://mir db.org/miRDB](http://mir db.org/miRDB)) ([@b22-mmr-17-03-3647]), PicTar (<http://pictar.mdc-berlin.de>) ([@b23-mmr-17-03-3647]), PITA (<https://genie.weizmann.ac.il/pubs/mir07/mir07_data.html>) ([@b24-mmr-17-03-3647]) and TargetScan (<http://www.targetscan.org>) ([@b25-mmr-17-03-3647]) databases, the miRNA-mRNA relationships involving the genes in each cluster were predicted. P\<0.05 and the involvement of at least 2 genes were used as the thresholds for screening significant miRNAs. Subsequently, the screened miRNA-mRNA pairs were visualized in miRNA-mRNA regulatory networks using Cytoscape software ([http://www.cyto scape.org](http://www.cyto scape.org)) ([@b26-mmr-17-03-3647]).

Based on the transcriptional regulatory data in the ENCyclopedia of DNA Elements (ENCODE) project (<http://www.genome.gov/Pages/Research/ENCODE>) ([@b27-mmr-17-03-3647]), the transcriptional regulatory relationships between the genes in each cluster were searched and identified. In addition, transcriptional regulatory networks were constructed using Cytoscape software ([@b26-mmr-17-03-3647]).

### PPI network construction and network integration

The STRING ([@b28-mmr-17-03-3647]) database (<http://string-db.org>) was applied to perform a PPI analysis for the genes in each cluster. The PPI pairs with a combined score (required confidence) \>0.4 were selected, after which, a PPI network was constructed using Cytoscape software ([@b29-mmr-17-03-3647]). Nodes were considered proteins in the PPI network, whereas their degrees corresponded to the number of interactions associated with them. Nodes with higher degrees were considered hub nodes ([@b30-mmr-17-03-3647]). Finally, the miRNA-mRNA regulatory network, transcriptional regulatory networks and PPI networks were integrated separately for the genes in each cluster.

### Functional and pathway enrichment analyses

The Gene Ontology database (GO; <http://www.geneontology.org/>) classifies functions according to three terms: Molecular function, biological process and cellular component ([@b31-mmr-17-03-3647]). The Kyoto Encyclopedia of Genes and Genomes database (KEGG; <http://www.genome.jp/kegg/>) contains information regarding biological systems from systemic functional, genomic and chemical aspects ([@b32-mmr-17-03-3647]). Using Database for Annotation, Visualization and Integrated Discovery software ([@b33-mmr-17-03-3647]), GO functional and KEGG pathway enrichment analyses were separately conducted for the genes involved in PPI networks. P\<0.05 and the involvement of at least 2 genes were used as the thresholds for screening significant terms.

Results
=======

### Clustering analysis

After preprocessing, cluster 1 \[including 292 genes; such as tripartite motif containing 28 (*TRIM28) and GAPDH*\], cluster 2 (including 111 genes), cluster 3 (including 194 genes) and cluster 4 \[including 103 genes; such as tumor necrosis factor (*TNF*)\] were obtained from soft clustering analysis. Genes in cluster 1 were significantly downregulated after 200 min and were significantly upregulated after 300 min. Genes in cluster 2 were continually downregulated, whereas genes in cluster 3 were continually upregulated. Genes in cluster 4 were significantly upregulated prior to 80 min and expression flattened after that time point ([Fig. 1](#f1-mmr-17-03-3647){ref-type="fig"}).

### Network construction and integration

Using the following thresholds: P\<0.05 and targeting at least 2 genes, miRNAs targeting the genes \[such as miRNA (miR)-146b-3p→TNF, miR-146b-5p→TNF and miR-142-5p→TNF\] in each cluster were enriched ([Table I](#tI-mmr-17-03-3647){ref-type="table"}). There were no miRNAs significantly enriched for the genes in cluster 2. Based on the ENCODE project, the transcriptional regulatory relationships between the genes in each cluster were searched and identified. In the transcriptional regulatory network for genes in cluster 1, *GAPDH* was targeted by *TRIM28*. However, no transcriptional regulatory relationships were found for the genes in cluster 3. There were 656, 40, 129 and 234 PPIs demonstrated in clusters 1, 2, 3 and 4. The top 10 nodes with the highest degrees in the PPI networks for each cluster are presented in [Table II](#tII-mmr-17-03-3647){ref-type="table"}, including *GAPDH* (degree, 40) in cluster 1, Janus kinase 2 (*JAK2*; degree, 10) and signal transducer and activator of transcription 5A (*STAT5A*; degree, 9) in cluster 3, and *TNF* (degree, 26) and *IL2* (degree, 22) in cluster 4. Finally, the regulatory and PPI networks were integrated separately for the genes in clusters 1 ([Fig. 2](#f2-mmr-17-03-3647){ref-type="fig"}), 2 ([Fig. 3](#f3-mmr-17-03-3647){ref-type="fig"}), 3 ([Fig. 4](#f4-mmr-17-03-3647){ref-type="fig"}) and 4 ([Fig. 5](#f5-mmr-17-03-3647){ref-type="fig"}).

### Functional and pathway enrichment analyses

GO functional and KEGG pathway enrichment analyses were conducted for the genes involved in the PPI networks. The top 10 functions enriched for the genes involved in the PPI networks are listed in [Table III](#tIII-mmr-17-03-3647){ref-type="table"}. Genes in the PPI networks were enriched in functions including negative regulation of protein metabolic process (cluster 1; P=2.39×10^−9^), defense response (cluster 2; P=2.84×10^−3^), response to organic substance (cluster 3; P=2.20×10^−5^), and immune response (cluster 4; P=3.43×10^−8^; which involved *IL2* and *TNF*). The top 10 pathways enriched for the genes involved in the PPI networks are presented in [Table IV](#tIV-mmr-17-03-3647){ref-type="table"}, including proteasome (cluster 1; P=8.10×10^−4^), toll-like receptor signaling pathway (cluster 2; P=2.26×10^−2^), cytokine-cytokine receptor interaction (cluster 3; P=6.80×10^−4^), and T cell receptor signaling pathway (cluster 4; P=1.41×10^−5^; which involved *IL2* and *TNF*).

Discussion
==========

In the present study, cluster 1 (including 292 genes), cluster 2 (including 111 genes), cluster 3 (including 194 genes) and cluster 4 (including 103 genes) were obtained from soft clustering analysis. Genes in cluster 1 were significantly downregulated after 200 min and were significantly upregulated after 300 min. Genes in cluster 2 and cluster 3 had evidently opposite tendencies. Genes in cluster 4 were significantly upregulated prior to 80 min and expression plateaued thereafter. The miRNA-mRNA pairs, TF-mRNA pairs and PPI relationships were searched, respectively. There were no miRNAs significantly enriched for the genes in cluster 2, and no transcriptional regulatory relationships were determined for the genes in cluster 3. There were 656, 40, 129 and 234 PPIs for genes in clusters 1, 2, 3 and 4, respectively. In particular, *GAPDH* (degree, 40) in cluster 1, *JAK2* (degree, 10) and *STAT5A* (degree, 9) in cluster 3, and *TNF* (degree, 26) and *IL2* (degree, 22) in cluster 4 exhibited high degrees in the PPI networks.

The *gapA* gene that encodes GAPDH is conserved in numerous serotypes of *Haemophilus parasuis*, and the GAPDH (*pCgap*) DNA vaccine may contribute to the immune response and inhibit infection with *H. parasuis* ([@b34-mmr-17-03-3647]). A previous study demonstrated that *GAPDH* in *Streptococcus agalactiae* can function as a virulence-associated immunomodulatory protein ([@b35-mmr-17-03-3647]). As a component of heterochromatin complexes, *TRIM28* is phosphorylated following stimulation by the T cell antigen receptor, and is implicated in T cell activation and tolerance ([@b36-mmr-17-03-3647]). In the transcriptional regulatory network for genes in cluster 1, *GAPDH* was targeted by *TRIM28*, indicating that *TRIM28* may have a role in Treg function through targeting *GAPDH*. *JAK2* propagates receptor-binding signals through inflammatory cytokines, and can serve as a relevant biological target in the control of allograft rejection or grading acute graft-versus-host disease without broader immune impairment ([@b37-mmr-17-03-3647]). Genome-wide association studies have reported that the JAK-STAT signaling pathway is highly correlated with human autoimmunity, and targeting various JAKs has been applied in immune-mediated disease ([@b38-mmr-17-03-3647]). These findings indicated that *JAK2* may also be associated with Treg function.

In the miRNA-mRNA regulatory network for genes in cluster 4, *TNF* was targeted by *miR-146b-3p, miR-146b-5p* and *miR-142-5p*. Suppression or stimulation of the costimulators of TNF receptor family (TNFR) members may be used to treat cancer, autoimmunity, infectious disease and transplantation ([@b39-mmr-17-03-3647]). Through quantitative polymerase chain reaction and flow cytometry, previous studies have indicated that anti-TNF antibody (infliximab) can increase *FOXP3* expression in CD4^+^CD25^high^ Tregs and restore the suppressive function of Tregs, thus suggesting that *TNF* may have a role in controlling autoimmunity through suppressing CD4^+^CD25^+^ Treg activity ([@b40-mmr-17-03-3647],[@b41-mmr-17-03-3647]). In addition, the stimulation of glucocorticoid-induced TNFR-related protein conquers self-tolerance/ignorance and promotes T cell-mediated antitumor activity with minimal autoimmunity ([@b42-mmr-17-03-3647],[@b43-mmr-17-03-3647]). miR-146a is ubiquitously expressed in Tregs and has an important role in congenital and acquired immune responses ([@b44-mmr-17-03-3647],[@b45-mmr-17-03-3647]). The results of a western blot analysis and enzyme-linked immunosorbent assay indicated that *miR-142-3p* controls the levels of cyclic adenosine monophosphate via regulating adenylyl cyclase 9 mRNA in CD4^+^CD25^+^ Treg cells and CD4^+^CD25^−^ T cells ([@b46-mmr-17-03-3647],[@b47-mmr-17-03-3647]). Therefore, *miR-146b-3p, miR-146b-5p* and miR-142-5p may serve roles in Treg function via regulating *TNF*.

*STAT5* binds to the *FOXP3* promoter, indicating that activation of IL-2 receptor β-dependent *STAT5* contributes to Treg differentiation by mediating *FOXP3* expression ([@b48-mmr-17-03-3647]). *STAT5a/b* have been demonstrated to serve a nonredundant, essential role in regulating Tregs, and have an opposing role compared with *STAT3* in regulating *FOXP3* ([@b49-mmr-17-03-3647]). Flow cytometric analysis indicated that *STAT5B* transfers a crucial IL-2-mediated signal that promotes the accumulation of functional Tregs *in vivo* ([@b50-mmr-17-03-3647]). *STAT5* activation maintains the expression of *FOXP3* in CD4^+^CD25^−^ effector T cells and Tregs, thus indicating the influential role of cytokines on *FOXP3* expression ([@b51-mmr-17-03-3647]). These findings indicated that *IL2* and *STAT5A* may be implicated in Treg function. Enrichment analyses demonstrated that *IL2* and *TNF* were enriched in immune response and T cell receptor signaling pathway, suggesting that *IL2* and *TNF* may affect Treg function via the immune response and T cell receptor signaling pathway.

In conclusion, cluster 1 (including 292 genes), cluster 2 (including 111 genes), cluster 3 (including 194 genes) and cluster 4 (including 103 genes) were obtained from a soft clustering analysis. Subsequently, *GAPDH* was revealed to be targeted by *TRIM28*, and *TNF* was targeted by *miR-146b-3p*, *miR-146b-5p* and *miR-142-5p*; these interactions in addition to *JAK2*, *IL2* and *STAT5A* may have important roles in Treg function. However, these findings, which were obtained by bioinformatics analysis, require further experimental verification.
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![Integrated network of the miRNA-mRNA regulatory network, transcriptional regulatory network and PPI network for the genes in cluster 1. Green nodes represent downregulated genes; triangles indicate transcription factors; blue diamonds indicate miRNAs; arrows represent transcriptional regulatory relationships; T-shaped lines indicate miRNA regulatory relationships; lines represent PPI relationships. miRNA, microRNA; PPI, protein-protein interaction.](MMR-17-03-3647-g01){#f2-mmr-17-03-3647}

![Integrated network of the transcriptional regulatory network and PPI network for the genes in cluster 2. Green nodes represent downregulated genes; triangles indicate transcription factors; arrows represent transcriptional regulatory relationships; lines represent PPI relationships. PPI, protein-protein interaction.](MMR-17-03-3647-g02){#f3-mmr-17-03-3647}

![Integrated network of the miRNA-mRNA regulatory network and PPI network for the genes in cluster 3. Red nodes represent upregulated genes; blue diamonds indicate miRNAs; T-shaped lines indicate miRNA regulatory relationships; lines represent PPI relationships. miRNA, microRNA; PPI, protein-protein interaction.](MMR-17-03-3647-g03){#f4-mmr-17-03-3647}

![Integrated network of the miRNA-mRNA regulatory network, transcriptional regulatory network and PPI network for the genes in cluster 4. Red nodes represent upregulated genes; triangles indicate transcription factors; blue diamonds indicate miRNAs; arrows represent transcriptional regulatory relationships; T-shaped lines indicate miRNA regulatory relationships; lines represent PPI relationships. miRNA, microRNA; PPI, protein-protein interaction.](MMR-17-03-3647-g04){#f5-mmr-17-03-3647}

###### 

miRNAs predicted for the genes in each cluster.

  Cluster   miRNA               Gene number   Gene symbol                                        P-value
  --------- ------------------- ------------- -------------------------------------------------- -------------
  1         *hsa-miR-204*       2             *ARPC1B*, *CDC25B*                                 3.22×10^−2^
            *hsa-miR-338-3p*    2             *BAX*, *COX8A*                                     4.29×10^−2^
            *hsa-miR-338-5p*    2             *BAX*, *COX8A*                                     4.29×10^−2^
            *hsa-miR-137*       2             *BAX*, *COX8A*                                     4.67×10^−2^
  3         *hsa-miR-28-5p*     3             *BCL6*, *JAK2*, *STAT5A*                           1.45×10^−3^
            *hsa-miR-28-3p*     3             *BCL6*, *JAK2*, *STAT5A*                           2.26×10^−3^
            *hsa-miR-339-3p*    2             *JAK2*, *RGS2*                                     3.22×10^−3^
            *hsa-miR-339-5p*    2             *JAK2*, *RGS2*                                     1.11×10^−2^
            *hsa-miR-127-3p*    2             *BCL6*, *PDGFA*                                    3.40×10^−2^
  4         *hsa-miR-146b-3p*   6             *CXCL8*, *IL10*, *MYC*, *NEDD9*, *NFKBIA*, *TNF*   2.84×10^−4^
            *hsa-miR-146b-5p*   6             *CXCL8*, *IL10*, *MYC*, *NEDD9*, *NFKBIA*, *TNF*   3.61×10^−4^
            *hsa-miR-125a-5p*   6             *CD40LG*, *CD80*, *CD83*, *IL10*, *LIF*, *MYC*     2.57×10^−3^
            *hsa-miR-139-5p*    2             *MYC*, *PTGS2*                                     8.51×10^−3^
            *hsa-miR-125a-3p*   5             *CD40LG*, *GADD45B*, *IL10*, *LIF*, *MYC*          9.01×10^−3^
            *hsa-miR-1224-5p*   2             *GADD45A*, *TNF*                                   1.12×10^−2^
            *hsa-miR-19a*       2             *NR4A2*, *TNF*                                     1.12×10^−2^
            *hsa-miR-455-5p*    2             *IL10*, *PTGS2*                                    1.12×10^−2^
            *hsa-miR-671-5p*    2             *GADD45A*, *RELB*                                  1.12×10^−2^
            *hsa-miR-142-5p*    3             *AHR*, *IL10*, *TNF*                               2.16×10^−2^
            *hsa-miR-630*       2             *GADD45A*, *YES1*                                  2.50×10^−2^
            *hsa-miR-34a*       2             *MYC*, *SIRT1*                                     3.83×10^−2^

miRNA, microRNA.

###### 

Top 10 nodes with higher degrees in the protein-protein interaction networks for each cluster.

  Gene           Degree
  -------------- --------
  Cluster 1      
    *GAPDH*      40
    *TSPO*       37
    *ISG15*      32
    *HSP90AB1*   31
    *OAS1*       24
    *OASL*       22
    *MX1*        21
    *PSMC3*      19
    *RPL8*       19
    *RPS3*       18
  Cluster 2      
    *IFIT1*        5
    *TUBA1A*       5
    *IRF7*         4
    *MAVS*         4
    *TUBA4A*       4
    *IFIT3*        4
    *HDAC4*        3
    *RGS19*        3
    *RPS6KA1*      3
    *FOS*          3
  Cluster 3      
    *JAK2*       10
    *STAT5A*       9
    *WDR43*        8
    *CTNNB1*       8
    *BCL6*         8
    *WDR36*        8
    *TSLP*         6
    *HSPD1*        6
    *MAK16*        6
    *CCR8*         5
  Cluster 4      
    *MYC*        27
    *TNF*        26
    *IL2*        22
    *ICAM1*      21
    *IL4*        18
    *CD40LG*     17
    *IL8*        17
    *RELB*       16
    *IL10*       15
    *NFKBIA*     14

###### 

Top 10 functions enriched for the genes involved in protein-protein interaction networks.

  Cluster   Description                                                             Gene number   Gene symbol                                                                                                                                                                                                P-value
  --------- ----------------------------------------------------------------------- ------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------
  1         GO:0051248\~negative regulation of protein metabolic process            18            *HSP90AB1, PSMB10, CLN3, PPP2R1A, NDUFA13, CDK5, PRKCD, FLNA, PSMB8, TGFB1, TIMP1, PSMB9, PSMC3, PSMB3, BAX, PSMD3, VPS28, PSMD8*                                                                          2.39×10^−9^
            GO:0032268\~regulation of cellular protein metabolic process            27            *HSP90AB1, PSMB10, EIF5A, ITGB2, STUB1, TGFB1, TIMP1, NR1H2, PSMB3, PSMD3, PSMD8, CD28, CLN3, PPP2R1A, CD3E, NDUFA13, CDK5, PRKCD, RPS5, PSMB8, PSMB9, PSMC3, BAX, CD81, HSPB1, VPS28, PPP1R15A*           7.78×10^−9^
            GO:0032269\~negative regulation of cellular protein metabolic process   17            *HSP90AB1, PSMB10, CLN3, PPP2R1A, NDUFA13, CDK5, PRKCD, PSMB8, TGFB1, TIMP1, PSMB9, PSMC3, PSMB3, BAX, PSMD3, VPS28, PSMD8*                                                                                9.96×10^−9^
            GO:0031400\~negative regulation of protein modification process         13            *PSMB10, PPP2R1A, CDK5, PRKCD, PSMB8, TGFB1, PSMB9, PSMC3, BAX, PSMB3, PSMD3, VPS28, PSMD8*                                                                                                                1.86×10^−7^
            GO:0006955\~immune response                                             30            *PSMB10, IFITM2, IFITM3, ACP5, CD70, IL32, OAS1, TGFB1, IFI35, MIF, TUBB, TMEM173, ZAP70, IL2RG, CD27, CD28, CD7, BST2, NCF4, HLA-B, PRKCD, PSMB8, HLA-G, BCAP31, PSMB9, GPI, CYBA, CORO1A, OASL, LIME1*   3.38×10^−7^
            GO:0070271\~protein complex biogenesis                                  23            *ARL2, PPP2R1A, OXA1L, POLR2E, CD3E, AP2S1, ALDOC, POLR2J, POLR2I, ARPC4, CDK5, TGFB1, FLNA, MIF, CYBA, TUBB, BAX, ALOX5AP, GTF2F1, CAPG, VAMP3, TUBA1C, SCO2*                                             5.68×10^−6^
            GO:0006461\~protein complex assembly                                    23            *ARL2, PPP2R1A, OXA1L, POLR2E, CD3E, AP2S1, ALDOC, POLR2J, POLR2I, ARPC4, CDK5, TGFB1, FLNA, MIF, CYBA, TUBB, BAX, ALOX5AP, GTF2F1, CAPG, VAMP3, TUBA1C, SCO2*                                             5.68×10^−6^
            GO:0031399\~regulation of protein modification process                  17            *PSMB10, PPP2R1A, CD3E, ITGB2, CDK5, PRKCD, STUB1, PSMB8, TGFB1, PSMB9, PSMC3, PSMB3, BAX, CD81, PSMD3, VPS28, PSMD8*                                                                                      8.00×10^−6^
            GO:0031397\~negative regulation of protein ubiquitination                 9           *PSMB10, PSMC3, PSMB3, PSMD3, VPS28, CDK5, PSMD8, PSMB8, PSMB9*                                                                                                                                            1.30×10^−5^
            GO:0065003\~macromolecular complex assembly                             26            *OXA1L, POLR2E, ALDOC, POLR2J, AP2S1, POLR2I, ARPC4, TGFB1, MIF, TUBB, ALOX5AP, SCO2, TUBA1C, ARL2, PPP2R1A, CD3E, CDK5, FLNA, CYBA, PIH1D1, DGAT1, GTF2F1, BAX, CAPG, SNRPB, VAMP3*                       1.65×10^−5^
  2         GO:0006952\~defense response                                              7           *MAVS, TNFAIP8L2, HDAC4, FOS, CCR5, IRF7, TLR1*                                                                                                                                                            2.84×10^−3^
            GO:0006954\~inflammatory response                                         5           *HDAC4, FOS, CCR5, IRF7, TLR1*                                                                                                                                                                             6.92×10^−3^
            GO:0006853\~carnitine shuttle                                             2           *SLC25A20, CPT2*                                                                                                                                                                                           7.08×10^−3^
            GO:0045892\~negative regulation of transcription, DNA-dependent           5           *HDAC4, IRF7, FOSB, KLF4, DNAJB6*                                                                                                                                                                          9.48×10^−3^
            GO:0051253\~negative regulation of RNA metabolic process                  5           *HDAC4, IRF7, FOSB, KLF4, DNAJB6*                                                                                                                                                                          1.00×10^−2^
            GO:0032365\~intracellular lipid transport                                 2           *SLC25A20, CPT2*                                                                                                                                                                                           1.64×10^−2^
            GO:0015838\~betaine transport                                             2           *SLC25A20, CPT2*                                                                                                                                                                                           1.64×10^−2^
            GO:0015879\~carnitine transport                                           2           *SLC25A20, CPT2*                                                                                                                                                                                           1.64×10^−2^
            GO:0006955\~immune response                                               6           *MAVS, TNFAIP8L2, GPR183, CCR5, TLR1, GPR65*                                                                                                                                                               2.18×10^−2^
            GO:0016481\~negative regulation of transcription                          5           *HDAC4, IRF7, FOSB, KLF4, DNAJB6*                                                                                                                                                                          2.22×10^−2^
  3         GO:0010033\~response to organic substance                               15            *BCL10, EIF2C2, STAT5A, TAF9B, HSPA1A, HSPA1B, CTNNB1, CYP7B1, ID2, TFRC, GNG10, PRKRA, HSPA6, JAK2, HSPD1, DNAJB4*                                                                                        2.20×10^−5^
            GO:0050867\~positive regulation of cell activation                        6           *BCL10, IL5, STAT5A, BCL6, JAK2, HSPD1*                                                                                                                                                                    3.07×10^−4^
            GO:0001817\~regulation of cytokine production                             7           *BCL10, REL, STAT5A, BCL6, JAK2, HSPD1, IL1A*                                                                                                                                                              3.97×10^−4^
            GO:0006325\~chromatin organization                                        9           *HIST1H2AC, KDM2B, HIST2H2BE, HIST1H2BG, HIST1H2AE, MORF4L2, EED, HIST1H3D, BCOR, HIST1H3H*                                                                                                                8.67×10^−4^
            GO:0006334\~nucleosome assembly                                           5           *HIST1H2AC, HIST2H2BE, HIST1H2BG, HIST1H2AE, HIST1H3D, HIST1H3H*                                                                                                                                           1.03×10^−3^
            GO:0031497\~chromatin assembly                                            5           *HIST1H2AC, HIST2H2BE, HIST1H2BG, HIST1H2AE, HIST1H3D, HIST1H3H*                                                                                                                                           1.18×10^−3^
            GO:0002761\~regulation of myeloid leukocyte differentiation               4           *IL5, ID2, STAT5A, CTNNB1*                                                                                                                                                                                 1.33×10^−3^
            GO:0010629\~negative regulation of gene expression                      10            *EIF2C2, ID2, JARID2, TAF9B, PRKRA, EED, BCL6, BCOR, RBPJ, CTNNB1*                                                                                                                                         1.36×10^−3^
            GO:0065004\~protein-DNA complex assembly                                  5           *HIST1H2AC, HIST2H2BE, HIST1H2BG, HIST1H2AE, HIST1H3D, HIST1H3H*                                                                                                                                           1.39×10^−3^
            GO:0034728\~nucleosome organization                                       5           *HIST1H2AC, HIST2H2BE, HIST1H2BG, HIST1H2AE, HIST1H3D, HIST1H3H*                                                                                                                                           1.51×10^−3^
  4         GO:0042127\~regulation of cell proliferation                            20            *IL4, NAMPT, TNF, FOSL2, IL8, PTGS2, KLF10, CTLA4, NFKBIA, IL13, SIRT1, SLAMF1, IL10, IL12RB2, LIF, CD80, MYC, PLAU, LTA, IL2*                                                                             6.12×10^−9^
            GO:0016265\~death                                                       19            *TRAF1, IER3, FOSL2, TNF, BCL2A1, NR4A2, NFKBIA, FASLG, BIRC3, SIRT1, AHR, GADD45G, ZC3H12A, SIAH2, TNFAIP3, GADD45B, GADD45A, MYC, LTA*                                                                   1.07×10^−8^
            GO:0001775\~cell activation                                             13            *IL4, ZBTB32, ICAM1, TNF, IL8, RELB, IL21R, SLAMF1, IL10, CD80, CD40LG, LTA, IL2*                                                                                                                          1.67×10^−8^
            GO:0006915\~apoptosis                                                   17            *TRAF1, IER3, TNF, BCL2A1, NFKBIA, FASLG, BIRC3, SIRT1, AHR, GADD45G, ZC3H12A, SIAH2, TNFAIP3, GADD45B, GADD45A, MYC, LTA*                                                                                 3.30×10^−8^
            GO:0006955\~immune response                                             18            *IL4, ICAM1, CCL3, TNF, IL18RAP, IL8, RELB, CTLA4, FASLG, IL13, GEM, CCL4, IL10, LIF, CD83, CD40LG, LTA, IL2*                                                                                              3.43×10^−8^
            GO:0012501\~programmed cell death                                       17            *TRAF1, IER3, TNF, BCL2A1, NFKBIA, FASLG, BIRC3, SIRT1, AHR, GADD45G, ZC3H12A, SIAH2, TNFAIP3, GADD45B, GADD45A, MYC, LTA*                                                                                 4.06×10^−8^
            GO:0042981\~regulation of apoptosis                                     19            *TRAF1, IL4, IER3, TNF, PTGS2, KLF10, BCL2A1, NR4A2, NFKBIA, FASLG, PIM3, BIRC3, SIRT1, IL10, CD40LG, TNFAIP3, MYC, LTA, IL2*                                                                              5.39×10^−8^
            GO:0008219\~cell death                                                  18            *TRAF1, IER3, FOSL2, TNF, BCL2A1, NFKBIA, FASLG, BIRC3, SIRT1, AHR, GADD45G, ZC3H12A, SIAH2, TNFAIP3, GADD45B, GADD45A, MYC, LTA*                                                                          6.26×10^−8^
            GO:0043067\~regulation of programmed cell death                         19            *TRAF1, IL4, IER3, TNF, PTGS2, KLF10, BCL2A1, NR4A2, NFKBIA, FASLG, PIM3, BIRC3, SIRT1, IL10, CD40LG, TNFAIP3, MYC, LTA, IL2*                                                                              6.26×10^−8^
            GO:0010941\~regulation of cell death                                    19            *TRAF1, IL4, IER3, TNF, PTGS2, KLF10, BCL2A1, NR4A2, NFKBIA, FASLG, PIM3, BIRC3, SIRT1, IL10, CD40LG, TNFAIP3, MYC, LTA, IL2*                                                                              6.62×10^−8^

###### 

The pathways enriched for the genes involved in protein-protein interaction networks (only the top 10 pathways are presented for cluster 4).

  Cluster   Description                                             Gene number   Gene symbol                                                                                        P-value
  --------- ------------------------------------------------------- ------------- -------------------------------------------------------------------------------------------------- -------------
  1         hsa03050:Proteasome                                       7           *PSMB10, PSMC3, PSMB3, PSMD3, PSMD8, PSMB8, PSMB9*                                                 8.10×10^−4^
            hsa05016:Huntington\'s disease                          13            *UQCRC1, POLR2E, NDUFB7, CREB3, SLC25A6, AP2S1, POLR2J, COX8A, POLR2I, GPX1, BAX, NDUFS3, AP2M1*   1.16×10^−3^
            hsa04142:Lysosome                                         9           *CLN3, AP1M1, PSAP, ACP5, NEU1, CTSA, ATP6V0D1, ATP6V0B, GBA*                                      6.71×10^−3^
            hsa04514:Cell adhesion molecules (CAMs)                   8           *ITGB7, ICAM2, ICAM3, ITGB2, HLA-B, SELPLG, HLA-G, CD28*                                           3.85×10^−2^
            hsa04650:Natural killer cell mediated cytotoxicity        8           *RAC2, ICAM2, LCK, CD247, ZAP70, ITGB2, HLA-B, HLA-G*                                              3.98×10^−2^
            hsa05130:Pathogenic *Escherichia coli* infection          5           *ARPC1A, ARPC1B, TUBB, ARPC4, TUBA1C*                                                              4.70×10^−2^
  2         hsa04620:Toll-like receptor signaling pathway             3           *FOS, IRF7, TLR1*                                                                                  2.26×10^−2^
  3         hsa04060:Cytokine-cytokine receptor interaction           9           *CCR8, TSLP, IL1R2, IL5, CCL20, CXCL3, CXCL2, IL1RAP, IL1A*                                        6.80×10^−4^
            hsa04062:Chemokine signaling pathway                      7           *CCR8, BRAF, CCL20, CXCL3, GNG10, CXCL2, JAK2*                                                     2.71×10^−3^
            hsa05322:Systemic lupus erythematosus                     5           *HIST1H2AC, HIST2H2BE, HIST1H2BG, HIST1H2AE, HIST1H3D, HIST1H3H*                                   6.60×10^−3^
            hsa04640:Hematopoietic cell lineage                       4           *IL1R2, IL5, TFRC, IL1A*                                                                           2.76×10^−2^
            hsa03010:Ribosome                                         4           *RPL23, RPL5, RPL37A, RPS24*                                                                       2.84×10^−2^
  4         hsa04060:Cytokine-cytokine receptor interaction         15            *IL4, CCL3, TNF, IL18RAP, IL8, IL21R, FASLG, IL13, CCL4, IL10, IL12RB2, LIF, CD40LG, LTA, IL2*     3.12×10^−9^
            hsa05330:Allograft rejection                              7           *IL4, TNF, CD80, CD40LG, FASLG, IL10, IL2*                                                         2.24×10^−7^
            hsa05320:Autoimmune thyroid disease                       7           *IL4, CD80, CD40LG, CTLA4, FASLG, IL10, IL2*                                                       1.91×10^−6^
            hsa04620:Toll-like receptor signaling pathway             8           *CCL3, TNF, CD80, IL8, MAP2K3, MAP3K8, NFKBIA, CCL4*                                               9.04×10^−6^
            hsa04660:T cell receptor signaling pathway                8           *IL4, TNF, CD40LG, MAP3K8, CTLA4, NFKBIA, IL10, IL2*                                               1.41×10^−5^
            hsa04630:Jak-STAT signaling pathway                       9           *LIF, IL12RB2, IL4, SPRY1, IL21R, IL13, MYC, IL10, IL2*                                            1.71×10^−5^
            hsa04010:MAPK signaling pathway                         11            *DUSP5, TNF, DUSP2, MAP2K3, RELB, MAP3K8, GADD45G, FASLG, GADD45B, GADD45A, MYC*                   2.21×10^−5^
            hsa05310:Asthma                                           5           *IL4, TNF, CD40LG, IL13, IL10*                                                                     6.12×10^−5^
            hsa04940:Type I diabetes mellitus                         5           *TNF, CD80, FASLG, LTA, IL2*                                                                       2.68×10^−4^
            hsa04672:Intestinal immune network for IgA production     5           *IL4, CD80, CD40LG, IL10, IL2*                                                                     4.89×10^−4^
